Cybin Inc N.CYBN

Alternate Symbol(s): CYBN

Healthcare Drug Manufacturers - Specialty & Generic

Cybin Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company creates psychedelic-based therapeutics to address the unmet need for treatment options for people who suffer from mental health conditions. Its N,N-dimethyltryptamine (DMT) and dDMT programs creates a dataset of systematic research on these psychedelic molecules. The Company is developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated dDMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. CYB003 moves to Phase III and CYB004 moves to Phase II. It has an intellectual property portfolio in the psychedelic drug development sector with over 30 patents granted and 160 patents pending. The Company operates in Canada, the United States, the United Kingdom, the Netherlands and Ireland.

NEO:CYBN - Post by User

Cybin Inc > Stock dilution

<< Previous

Bullboard Posts

Next >>

Comment by realitycheck00on Dec 07, 2020 1:50pm

101 Views

Post# 32050538

RE:Stock dilution

How, the shares are locked up and the intrinsic value of the acquisition should be added in. MMED now nearly $1B market cap and Cybin in my opinion still has lots of room to go.

<< Previous

Bullboard Posts

Next >>

Tilray Brands seeks US$250M for U.S. cannabis expansion